BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing
CompanyDeals

BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing

IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea
CompanyDeals

IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD
CompanyDeals

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development
CompanyDeals

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N
CompanyDeals

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
CompanyDrug

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC

Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%
Company

Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%

Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA
Company

Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax
CompanyDeals

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax

Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP
CompanyDeals

Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP

Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer
CompanyDrug

Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer

SSY Group Limited Projected to Win 12 Products in China’s Eleventh Volume‑Based Procurement Round
Policy / Regulatory

SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round